Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
“We might be able to have a big impact.” Since January 2023, two new drug treatments — Leqembi made by Eisai and Biogen and Kisunla made by Eli Lilly — have been approved by the Food and ...
About 6% of Leqembi is thrown away because there’s leftover drug after a dose is drawn to match a person’s weight Adding a 75-milligram vial could reduce waste by 74% and save Medicare as much ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
its drug for Alzheimer's disease, providing patients with another treatment option after Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi received the nod in September ...
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...